Modifying disease in rheumatoid arthritis
Relevant BNF section: 10.1.3
Rheumatoid arthritis affects about 1-2% of adults in the UK. Although the disease is sometimes mild, chronic synovitis, progressive destruction of articular cartilage and bone, and systemic manifestations commonly lead to marked disability and premature death.1,2 Disease-modifying antirheumatic drugs (DMARDs) are given to try to arrest or slow this deterioration. Until quite recently, DMARDs were started only when simpler measures (analgesics, physical treatments and non-steroidal anti-inflammatory drugs) had failed. Used in this way, DMARDs can suppress markers of disease activity and improve function and some have been shown to slow the progress of joint erosions.3 However, their impact on long-term disability has been disappointing. We discuss how these observations, and a fuller understanding of the pathogenesis and natural history of rheumatoid arthritis, have led to changes in the way DMARDs are used.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Anaesthesia
-
Infections
-
Malignant disease and immunosuppression
-
Haematology (drugs and medicines)
-
Musculoskeletal and joint disorders
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
